These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
313 related articles for article (PubMed ID: 16908524)
21. Serase-1B, a new splice variant of polyserase-1/TMPRSS9, activates urokinase-type plasminogen activator and the proteolytic activation is negatively regulated by glycosaminoglycans. Okumura Y; Hayama M; Takahashi E; Fujiuchi M; Shimabukuro A; Yano M; Kido H Biochem J; 2006 Dec; 400(3):551-61. PubMed ID: 16872279 [TBL] [Abstract][Full Text] [Related]
22. Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade. Le DM; Besson A; Fogg DK; Choi KS; Waisman DM; Goodyer CG; Rewcastle B; Yong VW J Neurosci; 2003 May; 23(10):4034-43. PubMed ID: 12764090 [TBL] [Abstract][Full Text] [Related]
23. Plasminogen activation by pro-urokinase in complex with its receptor--dependence on a tripeptide (Spectrozyme plasmin). Wang J; Mazar A; Quan N; Schneider A; Henkin J Eur J Biochem; 1997 Jul; 247(1):256-61. PubMed ID: 9249034 [TBL] [Abstract][Full Text] [Related]
24. The cleavage of pro-urokinase type plasminogen activator by stromelysin-1. Orgel D; Schröder W; Hecker-Kia A; Weithmann KU; Kolkenbrock H; Ulbrich N Clin Chem Lab Med; 1998 Sep; 36(9):697-702. PubMed ID: 9804393 [TBL] [Abstract][Full Text] [Related]
25. Tissue and urokinase plasminogen activators instigate the degeneration of retinal ganglion cells in a mouse model of glaucoma. Chintala SK Exp Eye Res; 2016 Feb; 143():17-27. PubMed ID: 26474495 [TBL] [Abstract][Full Text] [Related]
26. Single-chain urokinase-type plasminogen activator does not possess measurable intrinsic amidolytic or plasminogen activator activities. Husain SS Biochemistry; 1991 Jun; 30(23):5797-805. PubMed ID: 1828371 [TBL] [Abstract][Full Text] [Related]
27. Tissue-type plasminogen activator (tPA) interacts with urokinase-type plasminogen activator (uPA) via tPA's lysine binding site. An explanation of the poor fibrin affinity of recombinant tPA/uPA chimeric molecules. Novokhatny V; Medved L; Lijnen HR; Ingham K J Biol Chem; 1995 Apr; 270(15):8680-5. PubMed ID: 7721771 [TBL] [Abstract][Full Text] [Related]
28. Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin. Biliran H; Sheng S Cancer Res; 2001 Dec; 61(24):8676-82. PubMed ID: 11751384 [TBL] [Abstract][Full Text] [Related]
29. Proteolytic activation of pro-macrophage-stimulating protein by hepsin. Ganesan R; Kolumam GA; Lin SJ; Xie MH; Santell L; Wu TD; Lazarus RA; Chaudhuri A; Kirchhofer D Mol Cancer Res; 2011 Sep; 9(9):1175-86. PubMed ID: 21875933 [TBL] [Abstract][Full Text] [Related]
30. The cowpox virus serpin SPI-3 complexes with and inhibits urokinase-type and tissue-type plasminogen activators and plasmin. Turner PC; Baquero MT; Yuan S; Thoennes SR; Moyer RW Virology; 2000 Jul; 272(2):267-80. PubMed ID: 10873770 [TBL] [Abstract][Full Text] [Related]
32. Regulation of plasminogen activation by human U937 promonocytic cells. Duval-Jobe C; Parmely MJ J Biol Chem; 1994 Aug; 269(33):21353-7. PubMed ID: 8063761 [TBL] [Abstract][Full Text] [Related]
33. In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin. Festuccia C; Guerra F; D'Ascenzo S; Giunciuglio D; Albini A; Bologna M Int J Cancer; 1998 Jan; 75(3):418-31. PubMed ID: 9455804 [TBL] [Abstract][Full Text] [Related]
34. Elastase released from human granulocytes stimulated with N-formyl-chemotactic peptide prevents activation of tumor cell prourokinase (pro-uPA). Schmitt M; Kanayama N; Henschen A; Hollrieder A; Hafter R; Gulba D; Jänicke F; Graeff H FEBS Lett; 1989 Sep; 255(1):83-8. PubMed ID: 2529137 [TBL] [Abstract][Full Text] [Related]
35. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284 [TBL] [Abstract][Full Text] [Related]
36. Characterising the Subsite Specificity of Urokinase-Type Plasminogen Activator and Tissue-Type Plasminogen Activator using a Sequence-Defined Peptide Aldehyde Library. Li CY; de Veer SJ; Law RHP; Whisstock JC; Craik DJ; Swedberg JE Chembiochem; 2019 Jan; 20(1):46-50. PubMed ID: 30225958 [TBL] [Abstract][Full Text] [Related]
37. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor. Towle MJ; Lee A; Maduakor EC; Schwartz CE; Bridges AJ; Littlefield BA Cancer Res; 1993 Jun; 53(11):2553-9. PubMed ID: 8495419 [TBL] [Abstract][Full Text] [Related]
38. Inhibition of plasminogen activation protects against ganglion cell loss in a mouse model of retinal damage. Zhang X; Chaudhry A; Chintala SK Mol Vis; 2003 Jun; 9():238-48. PubMed ID: 12813409 [TBL] [Abstract][Full Text] [Related]
39. Inactivation of receptor-bound pro-urokinase-type plasminogen activator (pro-uPA) by thrombin and thrombin/thrombomodulin complex. Wilhelm S; Wilhelm O; Schmitt M; Graeff H Biol Chem Hoppe Seyler; 1994 Sep; 375(9):603-8. PubMed ID: 7840902 [TBL] [Abstract][Full Text] [Related]
40. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]